Clinical Trial: A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749586) titled 'A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors' on July 17.

Brief Summary: This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.

This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The investigational drug ARV-6723 will be given as an oral tablet on its own and also in combination with other drugs.

Researchers think that ARV-6723 can help the body's immune system to better recognize, attack, and de...